ID: MRFR/HC/3049-CRR | September, 2018 | Region: Global | 110 pages | Cooked Research Reports
Global Cell Culture Media Market Research Report, by Type (Lysogeny Broth, Classical Media, Custom Media, Other), by Application (Drug Discovery, Toxicity Testing, Other), by End-user (Biotechnology & Pharmaceutical Companies) - Global Forecast Till 2023
Cell culture medium is usually a liquid or gel designed to encourage the growth of microorganisms, cell lines, and cells. The medium contains amino acids, inorganic salts, vitamins, glucose, serum, and other vital nutrients for successfully growing various types of cells. The global cell culture media market is touted to exhibit a healthy 9.1% CAGR during the assessment period (2017-2023), as per a new market report by Market Research Future (MRFR).
The progress witnessed in stem cell research, biopharmaceuticals, and oncology is the major driver of the cell culture medium market. Emergence of various biotech startups and contract research organizations mushrooming to meet the demand for biopharmaceutical products can boost the market demand in the coming years. Rise in research and development (R&D) expenditure of various companies can augur the market as well. Lax policies regarding stem cell studies in developing economies is anticipated to boost the market demand. But challenges remain in the form of high costs of culture media, standardization, and chances of contamination.
The report covers the latest trends impacting the market to provide the most accurate forecasts and predictions. By correlating the historical data with upcoming market dynamics, our analysts can make highly astute projections. MRFR’s report includes a thorough analysis of the global cell culture media market segmented according to type, application, end-user, and region. Growth opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.
By type, the cell culture media market is segmented into chemically defined media, serum free media, protein free media, classical media, custom media, and lysogeny broth. Key market applications include stem cell research, genetic engineering, tissue engineering & biochemistry, toxicity testing, cancer research, and drug discovery & drug development. By end-user, the market is segmented into research laboratories, pathology labs, academic institutes, and biotechnology & pharmaceutical industries.
The segments covered in the report are analyzed with respect to four major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition of “cell culture media” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.
Some of the key players in the cell culture media market include HiMedia Laboratories (India), Thermo Fisher Scientific (U.S.), BD Biosciences (U.S.), Lonza (Switzerland), Corning Incorporated (U.S.), Merck KGaA (Germany), and GE Healthcare (U.S.). These players are engaged in partnerships to launch new products in the market and expand their consumer base. In 2017, GE Healthcare and the Austrian Center of Industrial Biotechnology collaborated to produce a cell line.
The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are discussed in granular detail.
At MRFR, our research analysts conduct a thorough objective analysis of the market when creating market reports by adhering to a rigorous set of standards which allow a truly comprehensive view of the market. Use of primary research strategies such as interviews with top-level decision makers of various biopharmaceutical companies and cell culture supply companies combined with secondary research provides a thorough analysis of past and present trends in a forward-looking manner. Additionally, market size estimation and validation use both top-down & bottom-up approaches to obtain data from the demand and supply-side. Credible resources are employed to assist analysts to understand the nuances of market factors with consistency. Competent data analysts use strong analytical tools to ascertain accurate analysis of very relevant parameters in an effort to provide clients with a conclusive and dependable view of the future.
For the scope of research, the report offers a comprehensive analysis of the global cell culture media market.
Cell Culture Media Market – Summary
The significant impact of the advancing technologies on life science has developed methods through which cells can now be cultured in artificial mediums. Cells, tissues or organs are obtained generally from plants or animals and are given conducive environment in which they can grow and deliver desired results. Usually, the medium consists amino acids, vitamins, inorganic salts, glucose, and serum that act as a spring of growth factors, hormones, and attachment factors and the aim is to maintain the pH level and osmolality. Its widespread use in laboratories for research purposes, in pharmaceutical to develop new medicines and significant impact on the cost-cutting measures of several sectors have made this a market favorite. The global cell culture media market can now envision a leap from USD 703.1 million to USD 1290.1 million during the forecast period (2017-2023).
The stellar CAGR of 9.1% can be attributed to mainly biotechnology sector where increasing investment by the government and private players are assisting in research and development activities. Researches are primarily aimed at producing vaccines to curb the effects of various diseases. In India, as per the India Brand Equity Foundation, the said industry is accounted for USD 11 billion in 2016. On the other hand, new bio firms are mushrooming all across the globe who can generate the demand for cell culture media market considerably.
However, the research process incurs a high cost, and the chance of medium getting contaminated due to serum and a poor source of animal components can adversely impact the market. On the flip side, manufacturing base in emerging countries such as India and China costs surprisingly less than other regions in the world which can steer the market away from such deterrents. Furthermore, labor-intensive production activities, if shifted to low wage and low regulatory regions, can fetch in economic incentives. And in such scenarios, India and China shine the best. These countries can promise a reduction in expenditure by almost 33% which is quite outstanding.
Type-based segmentation of the market includes lysogeny broth, chemically defined media, protein-free media, serum-free media, classical media, and custom media. Lysogeny broth with a 22.5% share of the global market is reigning supreme. Meanwhile, chemically defined media is showing prospects using which it can attain the fastest CAGR of 9.6% during the forecast period.
Application-wise the market consists drug discovery and drug development, toxicity testing, cancer research, genetic engineering, tissue engineering & biochemistry, and stem cell research. Drug discovery and drug development segment with about 23.8% of the market share is doing impressive work. Prevalence of cancer in many countries has inspired the cancer research segment into work harder which is why with a 9.7% CAGR this segment can grow during the review period.
Based on end-user, the market can be segmented into biotechnology & pharmaceutical companies, research laboratories, academic institutes, and pathology labs. Biotechnology & pharmaceutical companies have fetched in the largest share of the market and have a prospect to earn around USD 386.5 million by 2023. Demand for vaccines is giving the sub-segment much traction. Government and multinational initiatives are ensuring setups of research laboratories which can witness the fastest growth rate of CAGR 9.3% during the assessment period.
Geographic segmentation of the market reveals regions such as the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
The Americas financially contribute the most to the global valuation of the market. The region has a superlative infrastructure for research and developments banking on which the market is skyrocketing with a prospect to soar even higher in the foreseeable future. A massive patient pool, suffering from various chronic diseases are also a major driver for the regional growth of the market.
The European market has several nations contributing substantially to the growth of the market such as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Government initiatives in this region are noteworthy and commendable, at the same time, the market is all set to attain better treatment procedures which are triggering further growth.
The APAC market with several nations such as Japan, China, India, Australia, and South Korea promise a better-envisioned picture. The region has India and China who are attracting players from all over the world with their lucrative setup offers that can increase the profit margin of the investors sizably. Developing economies, and increasing number of efficient labors are playing significant roles in the region delivering the best of the results due to which the fastest CAGR seems reasonably expected.
Key players influencing the market are Thermo Fisher Scientific, Merck KGaA, and GE Healthcare. Strategic partnerships, collaboration, and new product launches are methods opted by many to strengthen their market position. For instance, in July 2015, Corning Incorporated launched HepatoCells followed by a distribution agreement with BioCision, LLC for its cell cryopreservation portfolio in November 2015.
Merck KGaA engages itself in regional expansion and new product launches to widen its market presence. As a result, in May 2017, Merck launched Industry’s first off-the-shelf cell culture media for perfusion processes.
GE Healthcare, on the other hand, in February 2017, started collaborating with the Austrian Centre of Industrial Biotechnology.
Among the others, Lonza, BD, HiMedia Laboratories, Corning Incorporated are prominent players in the market. PeproTech GmbH, Bio Elpida, ProBioGen are doing significant business.
Global Cell Culture Media Market: Competitive Landscape
In the global cell culture media market, major companies are opting for strategic partnerships and collaborations to strengthen their market position. Moreover, new product launches are the second most widely adopted a strategy by key market players. The key players involved in this strategy are Merck KGaA, Thermo Fisher Scientific, and GE Healthcare, among others.
Merck KGaA was established in the year 1968. With the 2015 merger of Sigma-Aldrich, Merck Millipore has a broad portfolio of 300,000 products and an expanded global footprint. The company is focused on product launches and partnerships to enhance its market presence. In May 2017, the company opened the first joint bioprocess scale-up lab with Stelis Biopharma in India. In the same year, Merck KGaA launched the first off-the-shelf cell culture media for perfusion processes.
GE Healthcare was incorporated in 1892. The company is engaged in strategic partnerships to increase its product portfolio and global presence. In April 2017, United BioPharma selected GE Healthcare’s FlexFactory to build late-stage clinical and commercial production capacity for biopharmaceuticals. In February 2017, the Austrian Centre of Industrial Biotechnology and GE Healthcare established a cell line engineering collaboration.
Thermo Fisher Scientific was founded in 1897. The company has adopted the new product launches strategy to hold its position in the global cell culture media market. In February 2017, Thermo Fisher Scientific launched the Gibco StemFlex Medium. Moreover, in September 2017, the company launched enhancements to the Gibco B-27 Plus Neuronal Culture System.
Lonza was established in 1897 and is one of the world’s leading suppliers to the pharmaceutical, biotech, and specialty ingredients markets. In September 2017, Lonza introduced the CytoSMART2 System, an updated version of Lonza’s popular CytoSMART System for live cell imaging. Additionally, in March 2016, Lonza launched PowerCHO Advance Media.
These players established themselves as major companies across the globe. They are investing in research and development, awareness, marketing, and technology advancement. They also focus on acquisitions, partnerships, collaborations, expansions, and new product launches to obtain the maximum market share.